Fig. 1

PGK1 and PGK2 mRNA levels in human cancer tissues and matched normal tissues. The data of PGK1 (a) and PGK2 (b) mRNA levels in human tumors and paired normal tissues were obtained from TCGA RNA-Seq datasets as log RSEM values (see “Materials and methods” section) and plotted. The fold changes of median PGK1 mRNA level in tumors compared to that in normal controls in four cancer types are provided. Significant changes in median PGK1 mRNA level between tumors and normal controls are marked with asterisks (*P < 0.05, **P < 0.01, ***P < 0.001, independent variable t test). PGK1/2 phosphoglycerate kinase 1/2, TCGA The Cancer Genome Atlas, ACC adrenocortical cancer, BLCA bladder urothelial carcinoma, BRCA breast carcinoma, CESC cervical and endocervical cancer, CHOL cholangiocarcinoma, COAD colon adenocarcinoma, COADREAD colon and rectum adenocarcinoma, DLBC diffuse large B-cell lymphoma, ESCA esophageal carcinoma, GBM glioblastoma multiforme, HNSC head and neck squamous cell carcinoma, KICH kidney chromophobe, KIRC kidney clear cell carcinoma, KIRP kidney papillary cell carcinoma, LAML lymphoblastic acute myeloid leukaemia, LGG brain lower grade glioma, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, MESO mesothelioma, OV ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, PCPG pheochromocytoma and paraganglioma, PRAD prostate adenocarcinoma, READ rectum adenocarcinoma, SARC sarcoma, SKCM skin cutaneous melanoma, STAD stomach adenocarcinoma, TGCT testicular germ cell tumor, THCA thyroid carcinoma, THYM thymoma, UCEC uterine corpus endometrioid carcinoma, UCS uterine carcinosarcoma, UVM uveal melanoma